OBJECTIVE - This multi-institutional phase I/II trial explored patient-assessed tolerance of increasingly hypofractionated (HPFX) radiation for low/intermediate risk prostate cancer.
FREE DAILY AND WEEKLY NEWSLETTERS OFFERED BY CONTENT OF INTEREST
Did you find this article relevant? Subscribe to UroToday-GUOncToday!
The fields of GU Oncology and Urology are advancing rapidly including new treatments, enrolling clinical trials, screening and surveillance recommendations along with updated guidelines. Join us as one of our subscribers who rely on UroToday as their must-read source for the latest news and data on drugs. Sign up today for blogs, video conversations, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.
METHODS - 347 patients enrolled from 2002 to 2010.
Three increasing dose-per-fraction schedules of 64. 7Gy/22fx, 58. 08Gy/16fx and 51. 6Gy/12fx were each designed to yield equivalent predicted late toxicity. Three quality of life (QoL) surveys were administered prior to treatment and annually upto 3years.
RESULTS - Bowel QoL data at 3years revealed no significant difference among regimens (p=0. 469). Bowel QoL for all regimens declined transiently, largely recovering by three years, with only the 22 fraction decrement reaching significance. Bladder outcomes at 3years were comparable (p=0. 343) although, for all patients combined, a significant decline was observed from the baseline (p=0. 008). Spitzer quality of life data revealed similarly excellent, 3-year means (p=0. 188). International erectile function data also revealed no significant differences at 3years although all measures except intercourse satisfaction worsened post-treatment.
CONCLUSIONS - Three-year QoL changes for bowel, bladder and SQLI were modest and similar for 3 HPFX regimens spanning 2. 94-4. 3Gy per fraction. These favorable patient-scored outcomes demonstrate the safety and tolerability of such regimens and may be leveraged to support further implementation of mild to moderately hypofractionated radiotherapy in the setting of low and intermediate-risk prostate cancer.
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology. 2016 Jan 02 [Epub ahead of print]
Jeffrey V Brower, Jeffrey D Forman, Patrick A Kupelian, Daniel G Petereit, Vinai Gondi, Colleen A Lawton, Nick Anger, Sandeep Saha, Rick Chappell, Mark A Ritter
Department of Human Oncology, University of Wisconsin Carbone Cancer Center, Madison, United States. , Wayne State University, Detroit, United States. , UCLA Medical Center, Los Angeles, United States. , John T. Vucurevich Cancer Center Institute, Rapid City, United States. , CDH Cancer Center, Warrenville, United States. , Medical College of Wisconsin, Milwaukee, United States. , Department of Human Oncology, University of Wisconsin Carbone Cancer Center, Madison, United States. , Department of Biostatistics and Medical Informatics, University of Wisconsin, Madison, United States. , Department of Biostatistics and Medical Informatics, University of Wisconsin, Madison, United States. , Department of Human Oncology, University of Wisconsin Carbone Cancer Center, Madison, United States.